The authors reply

Drug Safety

Volumn 35, Issue 12, 2012, Pages 1188-1190

  Toovey, Stephen ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Influenza virus infections; Mental disorders; Neurological disorders; Oseltamivir

Indexed keywords

OSELTAMIVIR;

ABNORMAL BEHAVIOR; ACCIDENT; AUDITORY HALLUCINATION; AUTOMUTILATION; COGNITIVE DEFECT; CONVULSION; DELIRIUM; DELUSION; ENCEPHALITIS; EPILEPSY; FEBRILE CONVULSION; HUMAN; ILLUSION; INJURY; JAPAN; LETTER; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROPSYCHIATRY; PANIC; PARASOMNIA; PERCEPTION DISORDER; PRIORITY JOURNAL; SUICIDE; VISUAL HALLUCINATION;

EID: 84868619513     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11641690-000000000-00000     Document Type: Letter

References (2)

1. JonesM, Hama R, Jefferson T, et al. Neuropsychiatric adverse events and oseltamivir for prophylaxis. Drug Saf 2012; 35 (12): 1187-8
2. Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008; 31: 1097-114